On Tuesday, June 20, 2017, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) supported, by a vote of 17-Yes to 2-No, with no abstentions, proposed cardiovascular claims for Victoza (liraglutide) injection, by Novo Nordisk.
Back to All Events
Earlier Event: May 25
Secretary's Advisory Committee on Human Research Protections
Later Event: June 21
Pediatric Subcommittee of the Oncologic Drugs Advisory Committee